ThomasE.OlenckiDO

Oncology • Columbus, OH

Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Olencki is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Olencki's full profile

Already have an account?

Office
320 W 10th Ave
Columbus, Ohio
Columbus, OH 43210
Phone+1 614-293-9868

Fax+1 614-293-7525
Is this information wrong?

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1984 - 1985
Beaumont Health (Royal Oak)Residency, Internal Medicine, 1981 - 1984
Michigan State University College of Osteopathic MedicineClass of 1980

Certifications & Licensure

OH State License 1993 - 2021

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Withdrawn
Phase 2
Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Start of enrollment: 2007 Nov 01
Completed
Phase 2
PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer Start of enrollment: 2008 Feb 01
Terminated
Phase 1
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Start of enrollment: 2008 Aug 01
Completed
Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Start of enrollment: 2012 Nov 09
Completed
Phase 1
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Start of enrollment: 2013 Jul 31
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
Mark Damante, Kristin Huntoon, David Gibbs, Dante Pezzutti, Thomas Olencki, J Bradley Elder> ;Neurosurgical Focus. 2023 Aug 1
6 citations
Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy.
Shaheer Khan, Jose Lutzky, Alexander N Shoushtari, Joanne Jeter, Brian Marr, Thomas E Olencki, Colleen M Cebulla, Mohamed Abdel-Rahman, J William Harbour, Naomi Sender...> ;Frontiers in Oncology. 2022 Jan 1
3 citations
Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy.
Kristin Huntoon, Mark Damante, Joshua Wang, Thomas Olencki, J. Bradley Elder> ;Current Problems in Cancer. 2021 Nov 18
49 citations
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Philip Friedlander, Adil Daud, Harriet M. Kluger, Sunil Red...> ;Journal for Immunotherapy of Cancer. 2021 Apr 1
62 citations
Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Moshe Chaim Ornstein, Sumanta K. Pal, Laura S. Wood, Jackie M Tomer, Brian P. Hobbs, Xuefei S Jia, Kimberly D Allman, Allison Martin, Thomas Olencki, Nancy B. Davis, T...> ;The Lancet. Oncology. 2019 Oct 1
25 citations
A phase I/II trial of cetuximab in combination with interleukin-12 administered to patients with unresectable primary or recurrent head and neck squamous cell carcinoma
Elizabeth L. McMichael, Brooke Benner, Lakhvir S. Atwal, Nicholas B. Courtney, Xiaokui Mo, Melanie E. Davis, Amanda Campbell, Megan C. Duggan, Kallan Williams, Kyle A....> ;Clinical Cancer Research. 2019 May 29
1 citations
Successful Treatment and Five Years of Disease-free Survival in a Donor Transmitted Metastatic Melanoma with Ipilimumab Therapy.
Priyamvada Singh, Deepali Pandey, Brad H. Rovin, Todd E. Pesavento, Thomas Olencki> ;Cureus. 2019 May 14
5 citations
A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.
Lorena P. Suarez-Kelly, Kala M. Levine, Thomas Olencki, Sara E. Martin del Campo, Elizabeth A. Streacker, Taylor R. Brooks, Volodymyr Karpa, Joseph Markowitz, Anissa B...> ;Cancer Immunology, Immunotherapy. 2019 Feb 6
22 citations
Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab‐induced bullous pemphigoid
Alyson V. Ridpath, Polina V. Rzepka, Sabrina M. Shearer, Scott Scrape, Thomas Olencki, Benjamin H. Kaffenberger> ;International Journal of Dermatology. 2018 Nov 1
15 citations
Preserved Renal Allograft Function and Successful Treatment of Metastatic Merkel Cell Cancer Post Nivolumab Therapy.
Priyamvada Singh, Jon Visger Von, Jason Prosek, Brad H. Rovin, Todd E. Pesavento, Thomas Olencki, Deepali Pandey> ;Transplantation. 2018 Oct 1
5 citations
Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised ...
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara K. Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Da...> ;European Journal of Cancer. 2018 Sep 27
197 citations
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.
Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Rachel C. Blitzblau, Glen M. Bowen, Carlo M. Contreras, Gregory A. Daniels, ...> ;Journal of the National Comprehensive Cancer Network. 2018 Jun 1
240 citations
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Phillip A. Friedlander, Adil Daud, Harriet M. Kluger, Sunil...> ;Journal of Clinical Oncology. 2018 Jun 1
220 citations
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progress...
Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben L. Sanford, M. Dror Michaelson, Olwen Hahn, Meghara K. Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker R. Da...> ;European Journal of Cancer. 2018 Mar 20
26 citations
Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients.
Erica S. Tarabadkar, Hannah Thomas, Astrid Blom, Upendra Parvathaneni, Thomas Olencki, Paul Nghiem, Shailender Bhatia> ;The American Journal of Case Reports. 2018 Apr 30
2 citations
Author Correction: Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration.
Joseph Markowitz, Jiang Wang, Zach Vangundy, Jia You, Vedat O. Yildiz, Lianbo Yu, Isaac P. Foote, Owen E. Branson, Andrew Stiff, Taylor R. Brooks, Brandon J. Biesiadec...> ;Scientific Reports. 2018 Mar 6
222 citations
Guidelines of care for the management of basal cell carcinoma.
Christian L. Baum, Jeremy S. Bordeaux, Marc Brown, Klaus Busam, Daniel B. Eisen, Vivek Iyengar, Clifford W. Lober, David J. Margolis, Jane Messina, Alexander R. Miller...> ;Journal of the American Academy of Dermatology. 2018 Mar 1
259 citations
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, David F. McDermott, Daniel C. Cho, Ulka N. Vaishampayan, Saby George, Thomas Olencki, Jamal Taraz...> ;The Lancet. Oncology. 2018 Mar 1
94 citations
Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
Bernard Escudier, Thomas Powles, Robert J. Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stéphane Oudard, Frederic Rolland, Piotr Tomczak, Daniel Castellano, Leonard ...> ;Journal of Clinical Oncology. 2018 Jan 8
57 citations
Nitric oxide mediated inhibition of antigen presentation from DCs to CD4 + T cells in cancer and measurement of STAT1 nitration
Joseph Markowitz, Jiang Wang, Zach Vangundy, Jia You, Vedat O. Yildiz, Lianbo Yu, Isaac P. Foote, Owen E. Branson, Andrew Stiff, Taylor R. Brooks, Brandon J. Biesiadec...> ;Scientific Reports. 2017 Nov 13
3 citations
Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
Kara K. Rossfeld, Erinn M. Hade, Alexandra Gangi, Matthew C. Perez, Emily N. Kinsey, Joanna Grabska, Ashley Ederle, Jonathan S. Zager, April K.S. Salama, Thomas Olenck...> ;International Journal of Surgery. Oncology. 2017 Oct 10
14 citations
Erratum: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma [Journal for Immunotherapy of Cancer., 5 (2017...
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Pet...> ;Journal for Immunotherapy of Cancer. 2017 Sep 28
61 citations
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870).
Roberto Pili, David I. Quinn, Hans J. Hammers, J. Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, Roberto A. Salas...> ;Clinical Cancer Research. 2017 Dec 1
35 citations
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma.
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'...> ;Journal for Immunotherapy of Cancer. 2017 Aug 15
22 citations
Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
James Kurtz, Georgia M. Beasley, Doreen M. Agnese, Kari Kendra, Thomas Olencki, Alicia M. Terando, J. Harrison Howard> ;The Journal of Surgical Research. 2017 Jun 15
Join now to see all

Journal Articles

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised ...
Toni K Choueiri, Olwen Hahn, Thomas Olencki, Eric J Small, Shaker Dakhil, Darren R Feldman, European Journal of Cancer

Authored Content

Corrigendum to ‘Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival Update’ [Eur J Cancer 94 (May 2018) 115–125]September 2018
Cabozantinib Versus Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (Alliance A031203 CABOSUN Randomised Trial): Progression-Free Survival by Independent Review and Overall Survival UpdateApril 2018